Setipafant | BN-50727 | CAS#132418-35-0 | PAF inhbitior

MedKoo Cat#: 328042 | Name: Setipafant

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Setipafant, BN-50727, is a platelet activating factor (PAF) inhibitors potentially for the treatment of ulcerative colitis.

Chemical Structure

Setipafant

CAS#132418-35-0

Theoretical Analysis

MedKoo Cat#: 328042

Name: Setipafant

CAS#: 132418-35-0

Chemical Formula: C26H23ClN6O2S

Exact Mass: 518.1292

Molecular Weight: 519.02

Elemental Analysis: C, 60.17; H, 4.47; Cl, 6.83; N, 16.19; O, 6.17; S, 6.18

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Setipafant; BN-50727; BN 50727; BN50727.

IUPAC/Chemical Name

6-(2-chlorophenyl)-N-(4-methoxyphenyl)-1-methyl-7,10-dihydro-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-9(8H)-carboxamide

InChi Key

DDJKTQDAEYPACV-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H23ClN6O2S/c1-15-30-31-22-13-28-24(18-5-3-4-6-20(18)27)23-19-11-12-32(14-21(19)36-25(23)33(15)22)26(34)29-16-7-9-17(35-2)10-8-16/h3-10H,11-14H2,1-2H3,(H,29,34)

SMILES Code

O=C(N(C1)CCC2=C1SC3=C2C(C4=CC=CC=C4Cl)=NCC5=NN=C(C)N53)NC6=CC=C(OC)C=C6

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 519.02 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hurst J, Ma X, Bazan HE. PAF binding to a single receptor in corneal epithelium plasma membrane. Invest Ophthalmol Vis Sci. 1999 Mar;40(3):790-5. PubMed PMID: 10067986. 2: Negro Alvarez JM, Miralles López JC, Ortiz Martínez JL, Abellán Alemán A, Rubio del Barrio R. Platelet-activating factor antagonists. Allergol Immunopathol (Madr). 1997 Sep-Oct;25(5):249-58. Review. PubMed PMID: 9395010. 3: Bazan HE, Tao Y. PAF antagonists as possible inhibitors of corneal epithelial defects and ulceration. J Ocul Pharmacol Ther. 1997 Jun;13(3):277-85. PubMed PMID: 9185044. 4: Bazan HE, Varner L. A mitogen-activated protein kinase (MAP-kinase) cascade is stimulated by platelet activating factor (PAF) in corneal epithelium. Curr Eye Res. 1997 Apr;16(4):372-9. PubMed PMID: 9134327. 5: de Boissieu D, Canarelli JP, Cordonnier C, Richard S, Léké A, Tarrade T, Postel JP, Dupont C. Effect of BN 50727 on pathological findings and tissue platelet activating factor levels during ileal ischemia in newborn piglets. J Pediatr Surg. 1996 Dec;31(12):1675-9. PubMed PMID: 8986985. 6: Krüll M, Dold C, Hippenstiel S, Rosseau S, Lohmeyer J, Suttorp N. Escherichia coli hemolysin and Staphylococcus aureas alpha-toxin potently induce neutrophil adhesion to cultured human endothelial cells. J Immunol. 1996 Nov 1;157(9):4133-40. PubMed PMID: 8892649. 7: Pruñonosa J, Solà J, Peraire C, Pla F, Lavergne O, Obach R. Determination of the anti-platelet-activating factor BN-50727 and metabolites in human urine by high-performance liquid chromatography using solid-phase extraction. J Chromatogr B Biomed Appl. 1996 Mar 3;677(2):388-92. PubMed PMID: 8704947. 8: Sobhani I, Bado A, Cherifi Y, Moizo L, Laigneau JP, Pospai D, Mignon M, Lewin. Helicobacter pylori stimulates gastric acid secretion via platelet activating factor. J Physiol Pharmacol. 1996 Mar;47(1):177-85. PubMed PMID: 8777297. 9: Miguélez R, Palacios I, Navarro F, Gutierrez S, Sanchez-Pernaute O, Egido J, González E, Herrero-Beaumont G. Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. J Lipid Mediat Cell Signal. 1996 Jan;13(1):35-49. PubMed PMID: 8821809. 10: Hurst JS, Bazan HE. Platelet-activating factor preferentially stimulates the phospholipase A2/cyclooxygenase cascade in the rabbit cornea. Curr Eye Res. 1995 Sep;14(9):769-75. PubMed PMID: 8529415. 11: Pruñonosa J, Parera L, Peraire C, Pla F, Lavergne O, Obach R. Determination of the anti-platelet-activating factor BN-50727 and its metabolites in human plasma by high-performance liquid chromatography-solid-phase extraction. J Chromatogr B Biomed Appl. 1995 Jun 23;668(2):281-90. PubMed PMID: 7581863. 12: Sobhani I, Bado A, Moizo L, Laigneau JP, Tarrade T, Braquet P, Lewin MJ. Platelet-activating factor stimulates gastric acid secretion in isolated rabbit gastric glands. Am J Physiol. 1995 Jun;268(6 Pt 1):G889-94. PubMed PMID: 7611410. 13: Hurst JS, Bazan HE. Activation of the phospholipase/cyclooxygenase cascade in the rabbit cornea by platelet-activating factor is challenged by PAF receptor antagonists. J Ocul Pharmacol Ther. 1995 Fall;11(3):329-37. Review. PubMed PMID: 8590265. 14: Girault J, Malgouyat JM, Lecomte G, Longueville D, Istin B, Fourtillan JB. Quantitative measurement of BN50727 in human plasma and urine by combined liquid chromatography/negative ion chemical ionization mass spectrometry using a particle beam interface. Biol Mass Spectrom. 1994 Sep;23(9):581-9. PubMed PMID: 7948051. 15: Guinot P. Clinical experience with platelet-activating factor antagonists. Past, present, and near future. Clin Rev Allergy. 1994 Winter;12(4):397-417. Review. PubMed PMID: 7743464. 16: Defaux JP, Thonier F, Baroggi N, Etienne A, Braquet P. Involvement of platelet-activating factor (PAF) in endotoxin- or ischaemia-induced intestinal hyperpermeability in the rat. J Lipid Mediat. 1993 May;7(1):11-21. PubMed PMID: 8358021. 17: Filep JG, Hermán F, Földes-Filep E, Schneider F, Braquet P. Dexamethasone-induced gastric mucosal damage in the rat: possible role of platelet-activating factor. Br J Pharmacol. 1992 Apr;105(4):912-8. PubMed PMID: 1324056; PubMed Central PMCID: PMC1908691. 18: Bourgain RH, Andries R, Esanu A, Braquet P. PAF-acether induced arterial thrombosis and the effect of specific antagonists. Adv Exp Med Biol. 1992;316:427-40. PubMed PMID: 1288104. 19: Braquet P, Esanu A. New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists. Agents Actions. 1991 Jan;32(1-2):34-6. Review. PubMed PMID: 2058466. 20: Braquet P, Laurent JP, Rolland A, Martin C, Pommier J, Hosford D, Esanu A. From ginkgolides to N-substituted piperidino-thieno diazepines, a new series of highly potent dual antagonists. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:929-37. Review. PubMed PMID: 1825436.